Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT - Insider Monkey

📈 RBC Capital maintains a Buy rating on Biogen (BIIB) with a price target of $208.00.

💰 Total revenue grew 6% year-over-year to reach $2.4 billion in the reported quarter.

📊 GAAP diluted EPS for the quarter was $1.64, reflecting improved profitability.

🔄 Product revenue increased 3% at constant currency and 1% at actual currency.

💊 Approximately 45% of total product revenue now originates from non-MS medicines.

🧠 Biogen's portfolio treats MS, SMA, Alzheimer's, and ALS globally.

🚀 Management is optimistic about the company's ongoing portfolio transformation.

📉 RBC analyst notes that some AI stocks may offer higher returns with limited downside risk.

Bullish Signals
  • RBC Capital maintains a Buy rating on Biogen with a specific price target of $208, indicating strong institutional confidence in the stock's valuation.
  • The company achieved a 6% year-over-year growth in total revenue to $2.4 billion, demonstrating resilient top-line performance.
  • GAAP diluted EPS reached $1.64 for the quarter, signaling healthy earnings generation despite market volatility.
  • Product revenue grew 3% on a constant currency basis, highlighting organic strength independent of exchange rate fluctuations.
  • The company has successfully diversified its revenue stream, with nearly half (45%) now coming from non-MS medicines.
  • Management's optimism regarding the portfolio transformation suggests a strategic shift toward broader therapeutic areas.
Risk Factors
  • RBC Capital analyst Brian Abrahams explicitly states that some AI stocks hold greater promise for delivering higher returns, suggesting Biogen may be less attractive compared to emerging tech sectors.
  • The article implies that Biogen faces competition from other high-growth sectors like artificial intelligence which are perceived as having limited downside risk.
Full Analysis
RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen Inc. (NASDAQ: BIIB) with a price target of $208 in a report released on July 7, 2025. The firm highlights the company as one of 13 cheap healthcare stocks with significant upside potential, citing recent financial performance and portfolio transformation. Biogen reported a 6% year-over-year increase in total revenue to $2.4 billion for the quarter, with GAAP diluted EPS reaching $1.64. Product revenue grew 3% on a constant currency basis and 1% at actual currency rates, driven by a diversifying portfolio where approximately 45% of total product revenue now comes from non-MS medicines. Management expresses optimism regarding the company's transformation away from its reliance on multiple sclerosis treatments. The article notes Biogen's global focus on discovering and delivering advanced therapies for serious diseases including Alzheimer's, ALS, and spinal muscular atrophy, though it concludes with a promotional pitch for other AI stocks.